BMC Gastroenterology最新文献

{"title":"Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries.","authors":"Marianna Vitaloni, Katell Maguet, Andi Carlan, Patricia Stack, Vincent de Jong, Ross Williams, Zorana Maravic","doi":"10.1186/s12876-025-03976-y","DOIUrl":"10.1186/s12876-025-03976-y","url":null,"abstract":"<p><strong>Background: </strong>The incidence of early-onset colorectal cancer (eoCRC), defined as CRC diagnosed in individuals under 50, is rising globally. Younger patients often face diagnostic delays and receive care pathways designed for older populations. These gaps highlight the need for tailored approaches to diagnosis, treatment, and support.</p><p><strong>Objective: </strong>This study aimed to explore the lived experiences and challenges of eoCRC patients across seven European countries to inform public health strategies and improve patient-centered care.</p><p><strong>Methods: </strong>We conducted qualitative focus groups with 47 eoCRC patients and survivors from France, Ireland, Italy, the Netherlands, Romania, Spain, and the United Kingdom. Discussions were analyzed using a thematic approach, focusing on three stages of the patient journey: pre-diagnosis, diagnosis, and post-diagnosis.</p><p><strong>Results: </strong>Participants highlighted several key challenges, including low awareness of CRC symptoms among younger populations, diagnostic delays linked to age and gender biases, and limited access to age-appropriate support services. Many participants reported significant quality-of-life (QoL) impacts related to disrupted careers, intimacy issues, and challenges managing family responsibilities during treatment. Psychological support, physiotherapy, and nutritional counseling were inconsistently available, with significant disparities across public and private healthcare systems.</p><p><strong>Conclusions: </strong>The findings underscore the urgent need for targeted public health campaigns to raise awareness of eoCRC, improved training for healthcare providers to reduce diagnostic delays, and expanded access to tailored support services. Addressing these gaps is critical to mitigating the growing burden of eoCRC and improving outcomes for younger patients.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"378"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of endoscopic retrograde cholangiopancreatography after Billroth II anastomosis: a comparison of gastroscope and duodenoscope.","authors":"Kang Ho Lee, Gwang Hyo Yim, Jimin Han, Han Taek Jeong","doi":"10.1186/s12876-025-03973-1","DOIUrl":"10.1186/s12876-025-03973-1","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic retrograde cholangiopancreatography (ERCP) in patients with Billroth II anastomosis is challenging due to post-surgical anatomical alterations. This study aims to compare the clinical outcomes of using a duodenoscope and a cap-assisted gastroscope in these patients.</p><p><strong>Methods: </strong>Seventy-nine patients with Billroth II anastomosis and a naïve papilla were included in the study. ERCP was performed using either a cap-assisted gastroscope (n = 45) or a duodenoscope (n = 34). The primary outcome was the cannulation success rates, while secondary outcomes included clinical success rates, cannulation time, procedure duration, and complications.</p><p><strong>Results: </strong>Afferent limb intubation was successful in 67.1% of patients. Among these, selective biliary cannulation (SBC) was achieved in 73.6%, with no significant difference between the two groups. However, cannulation time was significantly longer in the cap-assisted gastroscope group (7.6 min vs. 5.8 min, p = 0.011). Complications occurred only in the cap-assisted gastroscope group, including one perforation (2.2%) and two cases of pancreatitis (4.4%), though the overall complication rate was not significantly different. Among the 40 patients (50.7%) who failed ERCP, percutaneous transhepatic biliary drainage (PTBD) was the most common rescue intervention (55%), followed by other procedures, including percutaneous gallbladder drainage, repeated ERCP, surgery, and conservative treatment.</p><p><strong>Conclusions: </strong>Both cap-assisted gastroscopes and duodenoscopes are viable options for ERCP in patients with Billroth II anastomosis. However, cannulation time was significantly shorter in the duodenoscope group.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"373"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of liver transient elastography in detecting cirrhosis with esophageal and gastric varices and evaluating variceal severity.","authors":"Chaozhi Wang","doi":"10.1186/s12876-025-03982-0","DOIUrl":"10.1186/s12876-025-03982-0","url":null,"abstract":"<p><strong>Objective: </strong>To explore the application and clinical value of liver transient elastography (TE) in diagnosing and assessing the degree of liver cirrhosis combined with esophageal and gastric varices (EGV).</p><p><strong>Methods: </strong>We chose 136 patients with cirrhosis and EGV admitted to the Liver Disease Department of our hospital from December 2022 to December 2024. The patients were divided into mild EGV (n = 71), moderate EGV (n = 40), and severe EGV (n = 25) based on the gastroscopic results, and another 50 cases of healthy physical examination at the same period were admitted into the control group. All cases underwent liver TE, biochemical parameters, and immune parameters examination to observe the diagnostic efficacy of liver TE in cirrhosis combined with EGV and the degree of varices.</p><p><strong>Results: </strong>The differences in TBIL, ALT, AST, PTA, and other biochemical parameters between all of groups were not statistically significant (P > 0.05). The differences were not statistically significant for the four groups of IgM, IgG, and other immune indices (P > 0.05). There was no significant difference in blood flow among these groups (P > 0.05). The interior diameter (ID) of the portal vein, blood flow velocity, and liver stiffness values were significant (P < 0.05). Portal vein ID, blood velocity, and liver stiffness values showed well diagnostic efficacy in cirrhosis with EGV, and liver stiffness values were the best in evaluating cirrhosis with EGV (P < 0.05). Liver stiffness values were more effective in assessing the degree of varices in cirrhosis combined with EGV and the best in diagnosing cirrhosis combined with severe EGV (P < 0.05).</p><p><strong>Conclusion: </strong>The application of liver TE has a high value in diagnosing cirrhosis combined with EGV and their degree of varices, especially in identifying severe curves, which has good clinical value.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"379"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in microbial and metabolic profiles of mice fed with long-term high salt diet.","authors":"Huiying Tian, Xiaotang Gao, Hanlin Du, Zhuofeng Lin, Xianen Huang","doi":"10.1186/s12876-025-03929-5","DOIUrl":"10.1186/s12876-025-03929-5","url":null,"abstract":"<p><strong>Purpose: </strong>High salt diet (HSD) has been considered as a risk factor for the development of metabolic disorders. However, less is known about long-term implications of HSD. Therefore, the aim of this study was to conduct a preliminary investigation into the effects of mice feeding with long-term HSD on gut microbial and metabolic profiles.</p><p><strong>Methods: </strong>In this study, C57BL/6 J mice were fed with HSD for 22 weeks, after which fat and feces were collected. The composition of fecal microbiota was determined using 16S rRNA gene sequencing. Fecal metabolic profiling of mice was identified through untargeted ultrahigh-performance liquid chromatography-mass spectrometry. In addition, the serum levels of adipocytokines, including fibroblast growth factor 21 (FGF21) and adiponectin (APN), were measured.</p><p><strong>Results: </strong>Long-term HSD disrupted the growth performance of mice. Compared to those fed a normal salt diet, mice on a long-term HSD showed slower weight gain, as well as lower fat accumulation and serum levels of APN, while experiencing elevated blood pressure and levels of serum FGF21 and glucose. The 16S rRNA sequencing revealed changes in community richness and diversity, with long-term HSD affecting the abundance of certain gut microbiota, including Firmicutes, Christensenella, Barnesiella, and Lactococcus. Fecal metabolomic analysis also uncovered alterations in metabolites, such as myriocin, cerulenin, norcholic acid, 7-ketocholesterol, and prostaglandins B2. Further analysis indicated that these gut and microbiota and metabolites are predominantly involved in the lipid metabolism of the organism. Importantly, variations in these gut metabolites and microbiota were significantly correlated with body weight, fat accumulation, and the levels of FGF21 and APN.</p><p><strong>Conclusion: </strong>Long-term HSD affects physiological traits, alters gut metabolites profiles, and impacts the composition and function of gut microbiota, thus causes a certain impact on lipid metabolism.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"375"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of the epidemiology and risk factors for severity and recurrence of hypertriglyceridemia-induced acute pancreatitis.","authors":"Jiongdi Lu, Zhe Wang, Wentong Mei, Kaixin Peng, Liang Zhang, Gang Wang, Kedong Xu, Zheng Wang, Yunpeng Peng, Zipeng Lu, Xiaolei Shi, Guotao Lu, Li Wen, Feng Cao","doi":"10.1186/s12876-025-03954-4","DOIUrl":"10.1186/s12876-025-03954-4","url":null,"abstract":"<p><p>This systematic review aims to comprehensively assess the epidemiology and identify risk factors associated with the severity and recurrence of hypertriglyceridemia-induced acute pancreatitis (HTG-AP). A search of PubMed, Web of Science, and Cochrane databases was conducted to identify all relevant randomized controlled trials (RCTs), prospective, or retrospective cohort studies on HTG-AP. Data related to epidemiology and risk factors for severity and recurrence of HTG-AP were extracted and analyzed. Seventy-seven studies met the inclusion criteria, comprising 1 RCT, 21 prospective studies, and 55 retrospective studies. A total of 56,617 acute pancreatitis (AP) patients were included, of which 19.99% were diagnosed with HTG-AP (n = 11,315). Compared to non-HTG-AP patients, HTG-AP patients were more likely to be male (68.7% vs. 57.3%) and younger (mean age 41.47 ± 4.32 vs. 50.25 ± 7.70 years). HTG-AP patients exhibited higher mortality rates (up to 20% vs. 15.2%), increased severity (8.3% to 100% vs. 3.8% to 47.2%), and higher recurrence rates (up to 64.8% vs. 23.3%). Analysis of temporal trends from 2002 to 2023 showed a range of HTG-AP prevalence in overall AP patients from 1.6% to 47.6%, with a slight upward trend that was not statistically significant (P = 0.1081). Regional analysis indicated relatively stable prevalence in North America (P = 0.5787), Europe (P = 0.0881), other regions (P = 0.738), while prevalence in China showed a significant increase (P = 0.0119). Thirteen studies investigated risk factors affecting HTG-AP severity, with elevated serum triglyceride (TG) levels associated with increased risk of complications such as pancreatic necrosis, systemic inflammatory response syndrome (SIRS), shock, and multi-organ failure. Additional factors including high neutrophil-to-lymphocyte ratio (NLR), elevated levels of amylase and C-reactive protein (CRP), hypocalcemia, and hypoalbuminemia were also implicated in HTG-AP severity. Smoking history, poor lipid control (TG > 3.1 mmol/L), or recurrent hypertriglyceridemia during follow-up were identified as potential predictors of HTG-AP recurrence. Our findings indicate a stable global prevalence of HTG-AP within AP patients, but a notable increase in China, possibly attributed to socio-economic and dietary factors.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"374"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of outcomes between surgery and non-surgery after conversion therapy for advanced gastric cancer with unresectable factors: a systematic review and meta-analysis.","authors":"Jiaheng Wu, Xuetian Du, Yiqiang He, Shulin Xian","doi":"10.1186/s12876-025-03969-x","DOIUrl":"10.1186/s12876-025-03969-x","url":null,"abstract":"<p><strong>Background: </strong>Advanced gastric cancer (AGC) with unresectable factors presents a significant treatment challenge. Conventional treatments such as systemic chemotherapy, radiotherapy, and immunotherapy can delay disease progression but often yield limited outcomes. For stage III-IV gastric cancer with unresectable factors, conversion therapy based on chemotherapy can achieve tumor downstaging, providing a subset of patients with the opportunity for curative surgery. However, the efficacy of multimodal approaches combining chemotherapy, with or without immunotherapy, and conversion surgery compared to chemotherapy alone remains controversial.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of high-quality studies published between January 2014 and November 2024, assessing the role of surgery following conversion therapy in advanced gastric cancer. Relevant studies were retrieved from PubMed, Embase, and Web of Science databases. All included studies were observational; no randomized trials were available. Clinical data, including overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse event (AE) rates, were analyzed using RevMan 5.4.</p><p><strong>Results: </strong>Twelve observational cohort studies were included. Conversion surgery(CS) was associated with improved 1-year, 3-year, and 5-year OS rates (RR 0.38, 95% CI: 0.31-0.47; RR 0.64, 95% CI: 0.54-0.76; RR 0.77, 95% CI: 0.65-0.91, respectively) and increased 1-year and 3-year PFS rates (RR 0.57, 95% CI: 0.49-0.99; RR 0.67, 95% CI: 0.57-0.78, respectively). No significant difference in AE rates was observed between groups.</p><p><strong>Conclusions: </strong>Conversion surgery following chemotherapy in stage III-IV gastric cancer is associated with improved OS and PFS in observational studies. However, these findings may reflect inherent prognostic differences between groups, as surgery was only feasible for chemotherapy responders. Prospective trials are needed to validate causality.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"371"},"PeriodicalIF":2.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surface area outcomes in EUS-guided liver biopsy: a comparative study of Franseen and Fork-tip needles.","authors":"Kotaro Matsumoto, Shinpei Doi, Takako Adachi, Ayako Watanabe, Nobuhiro Katsukura, Takayuki Tsujikawa, Tatsuya Aso, Mikiko Takahashi, Kentaro Kikuchi","doi":"10.1186/s12876-025-03961-5","DOIUrl":"https://doi.org/10.1186/s12876-025-03961-5","url":null,"abstract":"<p><strong>Background: </strong>The practice of endoscopic ultrasound-guided liver biopsy (EUS-LB) is becoming more common due to its proven safety and effectiveness. For accurate diagnosis, it is vital to secure ample tissue specimens. However, gauging the volume of tissue specimens accurately poses a challenge with existing methods. Additionally, determining the most suitable fine-needle biopsy (FNB) needle requires further study. Our aim was to contrast the tissue surface areas obtained using Franseen and Fork-tip needles and to identify factors affecting tissue volume.</p><p><strong>Methods: </strong>This retrospective study analyzed liver tissue samples collected through EUS-LB using 19-gauge Franseen and Fork-tip needles from patients suffering from diffuse liver diseases, conducted in our hospital from April 2019 to April 2022. We primarily focused on measuring hepatic tissue surface area and portal tract count, alongside examining patient-related factors that could influence tissue surface area.</p><p><strong>Results: </strong>The study involved 20 cases for each type of needle. The comparison revealed no significant disparities in the total liver tissue surface area (22.0 mm² vs. 22.6 mm², P = 0.45) or in the portal tract counts (30 vs. 20, P = 0.16). No adverse incidents were noted in either group. Both univariate and multivariate analyses highlighted that fibrosis and metabolic dysfunction associated steatotic liver disease (MASLD) presence were significant determinants of the total hepatic tissue area (P = 0.04, P < 0.05; and P = 0.02, P = 0.03, respectively).</p><p><strong>Conclusion: </strong>The capabilities of both needles in acquiring liver tissue were comparably effective. The volume of tissue was affected by the severity of fibrosis and the occurrence of MASLD.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"370"},"PeriodicalIF":2.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The HbA1c/HDL-C ratio as a screening indicator of NAFLD in U.S. adults: a cross-sectional NHANES analysis (2017-2020).","authors":"Ju Wu, Wenjing Yu, Linglong Huang, Shuangshuang Hou, Yanan Huang, Zhihua Huang, Zhiyuan Dai, Jiajun Yin, Zhequn Nie","doi":"10.1186/s12876-025-03974-0","DOIUrl":"https://doi.org/10.1186/s12876-025-03974-0","url":null,"abstract":"<p><strong>Background: </strong>Non-alcoholic fatty liver disease (NAFLD), a metabolic liver disorder closely associated with obesity and diabetes, urgently requires early screening. This population-based study is the first to explore the relationship between glycemic control and a novel dyslipidemia composite index-the glycated hemoglobin/high-density lipoprotein cholesterol (HbA1c/HDL-C) ratio in individuals with NAFLD and liver fibrosis.</p><p><strong>Methods: </strong>Data from 5,891 adults in the 2017-2020 National Health and Nutrition Examination Survey (NHANES) were analyzed. Binary logistic regression and restricted cubic spline (RCS) analyses were used to evaluate the association between HbA1c/HDL-C ratio and the risk of NAFLD and liver fibrosis. The reliability of the results was confirmed using subgroup, interaction, and sensitivity analyses. Screening performance was assessed using receiver operating characteristic (ROC) curves, and differences between various indicators were compared using the DeLong test.</p><p><strong>Results: </strong>After adjusting for confounding factors, each 1% increase in the HbA1c/HDL-C ratio was associated with a 20% higher risk of NAFLD (odds ratio [OR] = 1.20, 95% confidence interval [CI]: 1.14-1.27, P < 0.001). Sensitivity analyses confirmed the robustness of these findings (P < 0.001). However, the associations with liver fibrosis (P = 0.064) and moderate-to-severe liver fibrosis (P = 0.130) were not statistically significant. Participants in the highest HbA1c/HDL-C quartile had significantly higher odds of NAFLD than those in the lowest quartile (OR = 2.21, 95% CI: 1.74-2.79). RCS analysis revealed a non-linear positive correlation between the HbA1c/HDL-C and NAFLD risk (P for non-linear = 0.003). Subgroup and interaction analyses showed that this association was more pronounced in the non-diabetic population. The ROC curve yielded an AUC of 0.713 for NAFLD screening.</p><p><strong>Conclusion: </strong>In U.S. adults, the HbA1c/HDL-C appears to be an effective tool for NAFLD screening. As a novel composite index, it also holds considerable reference value for identifying NAFLD risk in the non-diabetic population.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"369"},"PeriodicalIF":2.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders.","authors":"Hong-Ye Peng, Chun-Li Lu, Mo Zhao, Xiao-Qiang Huang, Shu-Xia Huang, Zi-Wen Zhuo, Jing Liu, Yan-Ping Lu, Wen-Liang Lv","doi":"10.1186/s12876-025-03912-0","DOIUrl":"https://doi.org/10.1186/s12876-025-03912-0","url":null,"abstract":"<p><strong>Objectives: </strong>Our objective was to compare the clinical features of Metabolic dysfunction-associated steatotic liver disease (MASLD) /metabolic alcohol-related liver disease (MetALD)/metabolic associated fatty liver disease (MAFLD)/nonalcoholic fatty liver disease (NAFLD) and the relative risk analysis of metabolic disorders.</p><p><strong>Methods: </strong>The National Health and Nutrition Examination Survey for the 2017-2018 cycle was used to screen the participants. Multivariate-adjusted logistic regression models were applied to explore the difference in relative risk analysis between NAFLD/MAFLD/MASLD/MetALD and metabolic disorders.</p><p><strong>Results: </strong>Among the 1,862 eligible individuals, 358(44.84%) had MASLD, 213(11.44%) had MetALD, 841(45.17%) had MAFLD, and 1,125(60.42%) had NAFLD. Positive associations with the risk of hypertension were discovered for MASLD (OR = 2.892, 95%CI = 2.226-3.756), MetALD (OR = 1.802, 95% CI = 1.355-2.398), MAFLD (OR = 3.455, 95%CI = 2.741-4.354) and NAFLD (OR = 1.983, 95%CI = 1.584-2.484). Positive associations with the risk of T2DM were discovered for MASLD (OR = 6.360, 95%CI = 4.440-9.109), MAFLD (OR = 7.026, 95%CI = 4.893-10.090) and NAFLD (OR = 3.372, 95%CI = 2.511-4.528). We discovered similar results for hyperlipidemia. Compared to mild steatosis, moderate to severe steatosis in patients with MASLD (OR = 3.924, 95%CI = 2.399-6.419), MAFLD (OR = 3.814, 95%CI = 2.367-6.144), NAFLD (OR = 4.910, 95%CI = 2.983-8.080) has a higher risk for T2DM.</p><p><strong>Conclusion: </strong>The proposed definitions of MASLD and MetALD are valuable and deserve further exploration. Our findings suggest that MAFLD is a more effective indicator for identifying patients at increased risk for metabolic disorders.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"372"},"PeriodicalIF":2.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red cell distribution width as a potential new biomarker to predict the clinical severity of acute diverticulitis.","authors":"Melek Yalcin Koc, Mehmet Aykut Yildirim, Suleyman Sakir Tavli, Abdullah Gurhan Duyan","doi":"10.1186/s12876-025-03975-z","DOIUrl":"10.1186/s12876-025-03975-z","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the relationships between red cell distribution width (RDW), other inflammation-related markers and clinical features with the clinical and radiological severity of diverticulitis.</p><p><strong>Methods: </strong>This retrospective cohort study included 250 patients diagnosed with acute diverticulitis. Radiological diverticulitis severity was determined by the Hinchey classification. Clinical diverticulitis severity was determined based on the treatment applied (invasive versus conservative/medical treatment).</p><p><strong>Results: </strong>High platelet count (p = 0.001) and high CRP (p < 0.001) were independently associated with the Hinchey Class II-IV. Need for invasive treatment was independently associated with presence of Hinchey stage II-IV (p < 0.001) and high (> 13.75) RDW (p < 0.001). With a cut-off value of > 13.75, RDW was able to predict patients requiring invasive treatment [Sensitivity = 75.86%, Specificity = 63.87%, AUC (95% CI) = 0.657 (0.580-0.734), p < 0.001].</p><p><strong>Conclusiosn: </strong>RDW, which is an inexpensive and readily-available parameter, may be a supportive measure in the prediction of the clinical severity of diverticulitis. Together with other clinical and laboratory data, RDW could help identify patients with worse prognosis, facilitating appropriate decisions and precautions in their management.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"366"},"PeriodicalIF":2.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}